Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Advanced Solid Tumors 483Solid Tumor 446Advanced Solid Tumor 414Unspecified Adult Solid Tumor, Protocol Specific 362Solid Tumors 336Mesothelioma, Malignant 324Mesothelioma 289Solid Tumor, Adult 124Carcinoma, Non-Small-Cell Lung 122Retinoblastoma 117Lung Neoplasms 77Ovarian Neoplasms 75Melanoma 65Sarcoma 62Carcinoma, Renal Cell 59Stomach Neoplasms 58Pancreatic Neoplasms 58Neoplasms 53Esophageal Neoplasms 53Small Cell Lung Carcinoma 52Colorectal Neoplasms 52Hematopoietic and Lymphatic System Neoplasm 50Uterine Cervical Neoplasms 46Breast Neoplasms 46Solid Tumours 35Neoplasm Metastasis 35Advanced or Metastatic Solid Tumors 35Squamous Cell Carcinoma of Head and Neck 34Carcinoma, Hepatocellular 32Triple Negative Breast Neoplasms 31

Interventions

Immune Checkpoint Inhibitors 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune-related Adverse Event × Other solid neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡